MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from investment
- note receivable
$5,000,000
Net proceeds from
exercises of warrants
$1,046,760
something is missing
$3,000,000
something is missing
$61,250
Net cash and cash
equivalents provided by...
$5,000,000
Net cash and cash
equivalents provided by...
$543,779
Effect of currency rate
exchange on cash and cash...
$2,587
Canceled cashflow
$3,000,000
Canceled cashflow
$564,231
Net increase
(decrease) in cash and cash...
$4,759,518
Canceled cashflow
$786,848
Investment in preferred
stock and warrants in...
$3,000,000
Change in fair value of
warrants - qcls
-$1,200,000
Stock issued for
compensation - rsus
$771,516
Net income (loss)
$746,860
something is missing
$469,000
Decrease in prepaid
expenses and other...
-$344,483
Change in fair value of
warrant asset femasys
-$214,000
Stock-based compensation -
options
$181,476
Increase in accounts
payable
$178,743
Unrealized loss on
marketable equity...
-$128,939
Repurchase of common stock,
net
$401,625
Payment of series c
convertible preferred stock...
$162,606
Net cash and cash
equivalents used in...
-$786,848
Canceled cashflow
$4,235,017
Change in fair value of
warrant liabilities
$1,895,865
Change in fair value of
investment qcls
$1,725,000
Change in fair value of
derivative liability
$557,000
Decrease in accrued
expenses
-$544,000
Non-cash interest income
$300,000
Back
Back
Cash Flow
source: myfinsight.com
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)